Interferon-γ-inducing factor elicits antitumor immunity in association with interferon-γ production

Journal of Immunotherapy

Volumn 21, Issue 1, 1998, Pages 48-55

  Tan, Jun ^c   Crucian, Brian E ^c   Chang, Alfred E ^a   Aruga, Etsuko ^a   Aruga, Atsushi ^a   Dovhey, Susan E ^c   Tanigawa, Keishi ^a   Yu, Hua ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c NONE

Author keywords

Antitumor; IFN ; IGIF; T cell immunity

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12;

ARTICLE; HUMAN; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; NATURAL KILLER CELL; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; GENE THERAPY; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-18; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RECOMBINANT PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031973446     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199801000-00006     Document Type: Article

References (24)

1. Okamura H, Tsutsul H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-γ production by T-cells. Nature 1996;378: 88-91.
2. Ushio S, Namba M, Okura T, et al. Cloning of the cDNA for human IFN-γ-inducing factor expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 1996; 156:4274-9.
3. Micallef JM, Ohtsuki T, Kohno K, et al. Interferon-γ-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 interferon-γ production. Eur J Immunol 1996;26:1647-51.
4. Schoenhaut DS, Chua AO, Wolitzky AG, et al. Cloning and expression of murine IL-12. J Immunol 1992;148:3433-40.
5. Gately MK, Warrier RR, Honasoge S, et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int Immunol 1994;6:157-67.
6. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993;178:1223-30.
7. Mu J, Zou JP, Yamamoto N, et al. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 1995;55: 4404-8.
8. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994;153:1697-706.
9. Zou J-P, Yamamoto T, Fujii T, et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed INF-γ production by anti-tumor T cells. Int Immunol 1995;7:1135-45.
10. Tahara H, Zeh HJ III, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994;54:182-9.
11. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12 effective delivery by genetically engineered fibroblasts. J Immunol 1995;155:1393-403.
12. Tahara H, Zitvogel L, Storkus WJ, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995;154:6466-74.
13. Meko JB, Yim JH, Tsung K, Norton JA. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res 1995;55:4765-70.
14. Rakhmilevich AL, Turner J, Ford MJ, et al. Gene gun-mediated skin transfection with IL-12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 1996;93:6291-6.
15. Tan J, Newton CA, Djeu J, et al. Injection of cDNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res 1996;56:3399-403.
16. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995;13:399-415.
17. Martinotti A, Stoppacciaro A, Vagliani M, et al. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol 1995;25:137-46.
18. Colombo MP, Vagliani M, Spreafico F, et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 1996;56:2531-4.
19. Vagliani M, Rodolfo M, Cavallo F, et al. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res 1996;56:467-70.
20. Coughlin CM, Wysocka M, Kurzawa HL, Lee WMF, Trinchieri G, Eck SL. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 1995;55:4980-7.
21. Zitvogel L, Robbins PD, Storkus WJ, et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 1996; 26:1335-41.
22. Noguchi Y, Richards EC, Chen Y-T, Old LJ. Influence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 1995;92:2219-23.
23. North RJ, Bursuker I. Suppression of generation of concomitant antitumor immunity by passively transferred suppressor T cells from tumor-bearing donors. J Exp Med 1984;54:47-56.
24. Mills C, North RJ. Tumor-specific suppressor T cells which inhibit the in vitro generation of cytolytic T cells from immune and early tumor-bearing host spleens. Transplantation 1985;39:202-8.